Article Dans Une Revue BMC Cancer Année : 2025

A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

Virginia Pubul
  • Fonction : Auteur
Urbano Anido
  • Fonction : Auteur
Maria San-Roman-Gil
  • Fonction : Auteur
Belen Llana
  • Fonction : Auteur
Paula Jimenez-Fonseca
  • Fonction : Auteur
Marta Benavent Viñuales
  • Fonction : Auteur
Eric Baudin
Maribel del Olmo-García
  • Fonction : Auteur
José Carlos Ruffinelli
  • Fonction : Auteur
Sergio Baldari
  • Fonction : Auteur
Maddalena Sansovini
  • Fonction : Auteur
Sara Cingarlini
  • Fonction : Auteur
Angelina Filice
  • Fonction : Auteur
Francesco Panzuto
  • Fonction : Auteur
Rosa Álvarez-Álvarez
  • Fonction : Auteur
Laurence Lousberg
  • Fonction : Auteur
Frank Aboubakar Nana
  • Fonction : Auteur
Jorge Hernando
  • Fonction : Auteur
Alejando García-Álvarez
  • Fonction : Auteur
Amparo García-Burillo
  • Fonction : Auteur
Guillermo Villacampa
  • Fonction : Auteur
Timon Vandamme
  • Fonction : Auteur
Nicola Fazio
  • Fonction : Auteur
Alice Durand
  • Fonction : Auteur

Résumé

Background: Everolimus is the only approved therapy for patients with advanced neuroendocrine tumors (NET) of lung and thymus and new treatment options are urgently needed. Expression of somatostatin receptor 2 (SSTR2) is frequently seen in functional imaging in lung-NETs opening the opportunity to treat SSTR2 positive patients with radioligand therapies (RLT). Retrospective data suggest a potential meaningful benefit of RLT directed to SSTR2 in lung-NET patients. Methods: The LEVEL trial is a randomized, open-label, phase III international trial of 177Lu-edotreotide versus everolimus in patients with progressive, locally advanced or metastatic, and well/moderately differentiated NETs of lung (typical/atypical) or thymic origin. Patients could be treatment-naïve or have progressed (PD) on somatostatin analogues or ≤ 2 additional systemic treatments. Prior RLT or mTOR inhibitors are not permitted. Eligible patients are randomly assigned 3:2 to 6 cycles of 177Lu-edotreotide (total administered activity 7.5 ± 0.7 GBq / cycle) or to oral everolimus 10 mg once daily until PD or unacceptable toxicity. Only patients with positivity in somatostatin receptor imaging will be included. CT or MRI scans are performed every 12 weeks until PD. Blood samples are analyzed at baseline, at 1st tumor assessment, and at PD for pharmacodynamic endpoints. Archival tumor tissue samples will be analyzed for ancillary studies. The primary endpoint is progression-free survival (PFS) according to RECIST v1.1 based on local investigator assessment. Secondary endpoints include overall survival, overall response rate, safety, and quality of life (EORTC QLQ-C30). The expected sample size is 120 patients to demonstrate statistical significant risk reduction of 46.4% (HR = 0.536) in PFS with the experimental treatment using an overall 5% two-sided alpha error with 80% power. An interim PFS analysis was included using the Lan-DeMets with O'Brian-Fleming-like boundaries. Discussion: The LEVEL trial will investigate if 177Lu-edotreotide has the potential to be incorporated as a standard treatment option for patients with NETs from the lung and Thymus.

Fichier principal
Vignette du fichier
s12885-025-13941-3.pdf (1.62 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-05022367 , version 1 (07-04-2025)

Licence

Identifiants

Citer

Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina-Cerrillo, et al.. A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). BMC Cancer, 2025, 25 (1), pp.613. ⟨10.1186/s12885-025-13941-3⟩. ⟨hal-05022367⟩
1318 Consultations
269 Téléchargements

Altmetric

Partager

  • More